UNSPSC 51113602: Oprelvekin

This classification denotes a therapeutic interleukin with the molecular formula C854H1411N253O235S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) HM5641GA6F, more generally known as oprelvekin. European Medicines Agency schedules oprelvekin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14704MIG. The term OPRELVEKIN is an International Non-Proprietary Name or INN. see World Health Organization INN reference publication, Volume 11, no. 3 1997, list 38.

UNSPSC 51113602 Oprelvekin is a Commodity code identifying a specific injectable medication used to stimulate platelet production in patients with chemotherapy-induced thrombocytopenia. State and local governments procure this drug through pharmacy benefit programs, Medicaid agencies, and health plans serving state employees and indigent populations. The work being solicited under this code centers on establishing supply relationships and distribution channels for pharmaceutical products, with recent activity showing state health agencies exploring direct-to-manufacturer procurement models to bypass traditional pharmacy benefit managers and group purchasing organizations. Issuing bodies include state health and human services departments managing Medicaid, employee health benefits, and indigent care programs; these agencies serve as the primary purchasers and contract holders.

The Texas Health and Human Services Commission posted a Request for Information (RFI) No. HHS0017013 on April 3, 2026, seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI solicits information from potential vendors about establishing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, with a focus on vendors' experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts based on negotiated net pricing models, and capability to implement value-based or outcomes-based agreements. This represents preliminary market-intelligence gathering rather than a formal competitive solicitation; no award value, budget range, or binding timeline has been established. The RFI documentation does not specify set-aside designations, incumbent contractor information, or specific funding allocations, indicating that the state intends to inform its future procurement strategy through vendor responses before issuing a formal Request for Proposal.